FNY Partners Fund’s ResMed RMD Stock Holding History

FNY Partners Fund’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-102,553	Closed	-$7.89M	–	578
2017 Q3	$7.89M	Buy	+102,553	New	+$7.84M	1.34%	16

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

FNY Partners Fund's RMD Position: Q4 2017 in Review

FNY Partners Fund sold out of ResMed (RMD) in Q4 2017, closing a stake of 102,553 shares — an estimated $7.89M sold.

FNY Partners Fund first reported a position in RMD in Q3 2017 and held it in 1 quarter. The position peaked at $7.89M in Q3 2017. 416 funds tracked by Wall St. Rank hold RMD as of Q4 2017.

FNY Partners Fund reported no remaining ResMed position as of Q4 2017 after selling out during the quarter.
FNY Partners Fund sold 102,553 ResMed shares in Q4 2017, an estimated $7.89M.
FNY Partners Fund first reported a position in ResMed in Q3 2017 and held it in 1 quarter.
FNY Partners Fund's ResMed position peaked at $7.89M in Q3 2017.
416 funds tracked by Wall St. Rank held ResMed as of Q4 2017.

Based on FNY Partners Fund's 13F filing for Q4 2017, filed 24 Jan 2018.